Michael Secora Ph.D.
Net Worth

Last updated:

What is Michael Secora Ph.D. net worth?

The estimated net worth of Dr. Michael Secora Ph.D. is at least $12,728,853 as of 13 Nov 2024. He owns shares worth $7,513,151 as insider, has earned $4,573,982 from insider trading and has received compensation worth at least $641,720 in Recursion Pharmaceuticals, Inc..

What is the salary of Michael Secora Ph.D.?

Dr. Michael Secora Ph.D. salary is $320,860 per year as Chief Financial Officer in Recursion Pharmaceuticals, Inc..

How old is Michael Secora Ph.D.?

Dr. Michael Secora Ph.D. is 42 years old, born in 1983.

What stocks does Michael Secora Ph.D. currently own?

As insider, Dr. Michael Secora Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Recursion Pharmaceuticals, Inc. (RXRX) Chief Financial Officer 1,499,631 $5.01 $7,513,151

What does Recursion Pharmaceuticals, Inc. do?

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

RXRX logo
RXRX
Recursion Pharmaceuticals, Inc.
$5.01

Michael Secora Ph.D. insider trading

Recursion Pharmaceuticals, Inc.

Dr. Michael Secora Ph.D. has made 27 insider trades between 2023-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 39,375 units of RXRX stock on 14 Aug 2024. As of 13 Nov 2024 he still owns at least 1,499,631 units of RXRX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 39,375 $2.22 $87,413
Sale
Class A Common Stock 15,000 $7.66 $114,870
Option
Class A Common Stock 39,375 $2.22 $87,413
Option
Stock Option (Right to Buy) 39,375 $2.22 $87,413
Option
Class A Common Stock 39,375 $2.22 $87,413
Sale
Class A Common Stock 15,000 $7.64 $114,630
Option
Stock Option (Right to Buy) 39,375 $2.22 $87,413
Sale
Class A Common Stock 15,000 $6.36 $95,370
Option
Class A Common Stock 39,375 $2.22 $87,413
Option
Class A Common Stock 39,375 $2.22 $87,413
Option
Stock Option (Right to Buy) 39,375 $2.22 $87,413
Sale
Class A Common Stock 15,000 $6.32 $94,755
Sale
Class A Common Stock 15,000 $6.32 $94,725
Option
Stock Option (Right to Buy) 39,375 $2.22 $87,413
Option
Class A Common Stock 39,375 $2.22 $87,413
Option
Stock Option (Right to Buy) 39,375 $2.22 $87,413
Sale
Class A Common Stock 15,000 $6.17 $92,505
Option
Class A Common Stock 39,375 $2.22 $87,413
Sale
Class A Common Stock 15,000 $6.35 $95,250
Option
Class A Common Stock 39,375 $2.22 $87,413
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 23,124 $7.58 $175,349
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $7.67 $191,650
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Option
Class A Common Stock 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $11.03 $275,825
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Option
Class A Common Stock 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $10.46 $261,375
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 1,067 $10.98 $11,720
Sale
Class A Common Stock 23,933 $10.43 $249,717
Sale
Class A Common Stock 25,000 $9.86 $246,550
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $6.85 $171,325
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $7.07 $176,775
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $8.69 $217,325
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $8.43 $210,625
Option
Class A Common Stock 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $8.9 $222,525
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Option
Class A Common Stock 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $9.27 $231,800
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Option
Class A Common Stock 37,500 $2.22 $83,250
Sale
Class A Common Stock 1,991 $14.36 $28,597
Sale
Class A Common Stock 13,150 $15.36 $202,023
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 9,859 $16 $157,734
Sale
Class A Common Stock 500 $14.05 $7,024
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 24,500 $13.62 $333,788
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $10.07 $251,850
Option
Class A Common Stock 37,500 $2.22 $83,250
Option
Stock Option (Right to Buy) 37,500 $2.22 $83,250
Sale
Class A Common Stock 25,000 $9.93 $248,300

Recursion Pharmaceuticals key executives

Recursion Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: